To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: SCD-044_Dose 3Drug: PlaceboDrug: SCD-044_Dose 1Drug: SCD-044_Dose 2
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 263
- Registration Number
- NCT04566666
- Locations
- 🇬🇪
Israeli - Georgian Medical Research Clinic Helsikor LLC, Tbilisi, Georgia
🇵🇱ClinicMed, Bialystok, Poland
🇵🇱Synexus Polska Sp. z o.o. Branch in Gdansk, Gdansk, Poland
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
- Conditions
- Osteoarthritis of Knee
- Interventions
- Drug: MM-II dose IDrug: MM-II dose IIDrug: MM-II dose IIIDrug: Placebo
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 397
- Registration Number
- NCT04506463
- Locations
- 🇺🇸
Sunpharma site no. 25, Riverside, California, United States
🇺🇸Sunpharma site no. 22, Miami, Florida, United States
🇺🇸Sunpharma site no. 12, Miami, Florida, United States
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Target Recruit Count
- 327
- Registration Number
- NCT04487860
- Locations
- 🇮🇳
Sun Pharma Site 25, Nashik, Maharashtra, India
🇺🇸Sun pharma site 30, Los Angeles, California, United States
🇺🇸Sun pharma site 31, Boston, Massachusetts, United States
Effect of Cequaâ„¢ in Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: CequaTM (Cyclosporine 0.09%) ophthalmic solution
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 135
- Registration Number
- NCT04357795
- Locations
- 🇺🇸
Kannarr Eye Care, 2521 N Broadway, Pittsburg, Kansas, United States
🇺🇸Eye Associates of Fort Myers, 4225 Evans Ave., Fort Myers, Florida, United States
🇺🇸Bowden Eye and Associates, 7205 Bonneval Road, Jacksonville, Florida, United States
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
- Conditions
- Active Psoriatic Arthritis
- Interventions
- Drug: matching placebo injectionsDrug: TILD
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 296
- Registration Number
- NCT04314531
- Locations
- 🇺🇸
Sunpharma site no. 12, Covina, California, United States
🇺🇸Sunpharma site no. 04, Miami Beach, Florida, United States
🇺🇸Sunpharma site no. 02, New Port Richey, Florida, United States
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
- Conditions
- Active Psoriatic Arthritis
- Interventions
- Drug: TILDDrug: matching placebo injections
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 510
- Registration Number
- NCT04314544
- Locations
- 🇨🇦
Sunpharma site 98, Trois-Rivières, Quebec, Canada
🇵🇱Sunpharma Site no. 95, Warsaw, Mazowiecki, Poland
🇵🇱Sunpharma Site no. 93, Bialystok, Poland
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 323
- Registration Number
- NCT04066504
- Locations
- 🇮🇹
ASST Spedali Civili di Brescia, Brescia, Italy
🇩🇪Universitaets-Hautklinik Kiel, Kiel, Germany
🇩🇪Klinikum rechts der Isar, München, Germany
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 130
- Registration Number
- NCT03997786
- Locations
- 🇵🇱
Site 57, Bialystok, Poland
🇵🇱Site 55, Gdańsk, Poland
🇵🇱Site 51, Katowice, Poland
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
- Conditions
- Pregnancy Related
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 200
- Registration Number
- NCT03992729
- Locations
- 🇺🇸
Christina Chambers, San Diego, California, United States
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT03927443